Search

Displaying results 4311 - 4320 of 5759 in total
  1. Drug

    Nizubaglustat

    go.drugbank.com/drugs/DB21603
    Investigational

    Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.

  2. Drug

    Nevadistinel

    go.drugbank.com/drugs/DB21632
    Investigational

    Nevadistinel has a monoisotopic molecular weight of 274.13 Da. … The usage of the INN stem '-stinel' in the name indicates that Nevadistinel is a N-methyl-D-aspartate (NMDA) receptor co-agonist.

  3. Drug

    Vicadrostat

    go.drugbank.com/drugs/DB21693
    Investigational

    Vicadrostat has a monoisotopic molecular weight of 317.06 Da.

  4. Drug

    Monlunabant

    go.drugbank.com/drugs/DB21537
    Investigational

    Monlunabant has a monoisotopic molecular weight of 590.11 Da.

  5. Drug

    Tizaterkib

    go.drugbank.com/drugs/DB21296
    Investigational

    Tizaterkib has a monoisotopic molecular weight of 494.2 Da.

  6. Drug

    Mizacorat

    go.drugbank.com/drugs/DB21458
    Investigational

    Mizacorat has a monoisotopic molecular weight of 494.21 Da.

  7. Drug

    GC-376 free acid

    go.drugbank.com/drugs/DB15796
    Experimental

    The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056].

  8. Drug

    Linaprazan glurate

    go.drugbank.com/drugs/DB21534
    Investigational

    Linaprazan glurate has a monoisotopic molecular weight of 480.24 Da.

  9. Drug

    Prolgolimab

    go.drugbank.com/drugs/DB16740
    Investigational

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
  10. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    In a randomized, double-blind clinical trial, treatment of aripiprazole lauroxil in adult patients with schizophrenia resulted in improvement of positive and negative symptoms scores at day 85 of treatment

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates